NCT05073835View on ClinicalTrials.gov

Semaglutide 2.4 mg in Patients With Poor Weight-loss

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

March 31, 2025

Study Completion Date

September 30, 2025

Conditions
ObesityDiabetesMetabolic Syndrome
Interventions
DRUG

Semaglutide 3 mg

Semaglutide 2.4 mg/week, subcutaneous injection. Treatment dose: 16 weeks of dose escalation + 52 weeks of study dose (i.e., 2.4 mg/week).

DRUG

Placebo

Placebo

Trial Locations (1)

WC1E 6JF

Janine Makaronids, London

All Listed Sponsors
lead

University College, London

OTHER